West Pharmaceutical Services, Inc.

(NYSE:WST) reported better than expected second quarter 2026 earnings.

The injectable solutions company reported adjusted earnings of $2.37 per share, beating the consensus of $2.08.

Net sales of $872.3 million increased 13.8% year over year, with organic growth of 12.7%, beating the consensus of $838.586 million.

HVP Products And GLP-1 Demand Drive Growth Proprietary Products sales of $722.6 million grew by 16.6% and increased 15.5% on an organic basis.